Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) have received a consensus rating of "Hold" from the ten analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $13.57.
Several equities research analysts have weighed in on the company. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Bicycle Therapeutics in a research report on Friday, October 2nd. Jefferies Financial Group reissued a "buy" rating and issued a $10.00 price target on shares of Bicycle Therapeutics in a report on Thursday, October 29th. Needham & Company LLC lowered their price objective on Bicycle Therapeutics from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, July 30th. Zacks Research raised shares of Bicycle Therapeutics from a "strong sell" rating to a "hold" rating in a report on Thursday. Finally, Wall Street Zen cut shares of Bicycle Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday.
View Our Latest Report on Bicycle Therapeutics
Bicycle Therapeutics Price Performance
BCYC stock opened at $3.37 on Monday. The business has a 50-day moving average price of $3.70 and a 200 day moving average price of $4.42. The company has a market capitalization of $236.20 million, a P/E ratio of -1.66 and a beta of 1.59. Bicycle Therapeutics has a 1-year low of $3.26 and a 1-year high of $7.83.
Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.25. Bicycle Therapeutics had a negative net margin of 169.75% and a negative return on equity of 26.02%. The business had revenue of $34.06 million for the quarter, compared to analyst estimates of $12.22 million. On average, analysts anticipate that Bicycle Therapeutics will post -2.11 earnings per share for the current fiscal year.
Institutional Trading of Bicycle Therapeutics
Hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC grew its holdings in shares of Bicycle Therapeutics by 72.8% in the first quarter. Renaissance Technologies LLC now owns 979,300 shares of the company's stock valued at $4,544,000 after purchasing an additional 412,700 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in Bicycle Therapeutics by 2.3% during the 1st quarter. Principal Financial Group Inc. now owns 1,174,625 shares of the company's stock worth $5,450,000 after buying an additional 26,353 shares in the last quarter. Eversept Partners LP lifted its holdings in Bicycle Therapeutics by 6.6% during the 1st quarter. Eversept Partners LP now owns 190,715 shares of the company's stock worth $885,000 after buying an additional 11,800 shares in the last quarter. Rangeley Capital LLC boosted its position in Bicycle Therapeutics by 76.0% in the 1st quarter. Rangeley Capital LLC now owns 232,260 shares of the company's stock valued at $1,078,000 after buying an additional 100,260 shares during the period. Finally, Vontobel Holding Ltd. boosted its position in Bicycle Therapeutics by 15.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 23,000 shares of the company's stock valued at $85,000 after buying an additional 3,000 shares during the period. Hedge funds and other institutional investors own 86.15% of the company's stock.
About Bicycle Therapeutics
(
Get Free Report)
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a focus on cancer. Founded in 2009, the company grew out of research at the University of Cambridge in the United Kingdom and has operations in Cambridge, UK, and Cambridge, Massachusetts. The company's proprietary Bicycle platform creates small, constrained peptides that can bind to specific biological targets. Bicycle Therapeutics is using this technology to develop treatments that may be designed to reach targets that are difficult for conventional drugs to access.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bicycle Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list.
While Bicycle Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.